ClinicalTrials.gg
Not yet recruitingNCT07854171CHDUpdated Oct 2, 2026

The Effect of Telerehabilitation Exercises in Children With Congenital Heart Disease

An interventional study of Inspiratory Muscle Training and Functional Inspiratory Muscle Training in Congenital Heart Disease, Telerehabilitation and Functional Inspiratory Muscle Training, sponsored by Izmir Democracy University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Izmir Democracy University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Heart Defects, Congenital with a site in Turkey — 11 open to participants now, 12 under way, none of them phase 3. Heart Defects, Congenital · Turkey.

Planned enrollment
17th of 18
32 · median 51
Started
2026
with 4 others
No phase
17 of 32
8 open now
Primary completion
2028-06
later than 10 of 11 live
Registered
32nd of 32
by date

Among the 32 studies in Heart Defects, Congenital with a site in Turkey, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 32nd registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

11 of the 32 studies in Heart Defects, Congenital with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Heart Defects, Congenital with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to investigate the effects of functional inspiratory muscle training on physical performance and quality of life in pediatric patients with congenital heart disease.

Read the detailed description

Congenital heart disease (CHD) is a common condition in newborns. As a congenital disorder, CHD is the leading cause of infant mortality. Recent advances in medical treatment and surgical procedures have improved survival rates among children with CHD. However, despite these developments, children with CHD may still exhibit muscle weakness, physical inactivity, reduced performance in activities of daily living, and a decline in health-related quality of life. Therefore, this study aims to investigate the effects of functional inspiratory muscle training on physical performance and quality of life in pediatric patients with CHD.

03

Conditions studied

  • Congenital Heart Disease
  • Telerehabilitation
  • Functional Inspiratory Muscle Training

Keywords

  • congenital heart disease
  • exercise
  • muscle strength
  • respiratory function tests
  • telerehabilitation
  • quality of life
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having been diagnosed with CHD,
  • Being between 8 and 18 years of age,
  • Being in stage I, II, or III according to the (NYHA) classification,
  • Having a stable clinical condition,
  • Volunteering to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Having a history of any orthopedic or neurological disease that could interfere with the tests and exercises to be performed,
  • Having a history of any mental or psychological disease that could interfere with the tests and exercises to be performed,
  • Having any infection that could interfere with the tests and exercises to be performed,
  • Having undergone cardiac surgery within the last 6 months,
  • Having a for the exercise test.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    İntervention group

    The telerehabilitation program will last a total of 8 weeks and will consist of two parts: 4 weeks of inspiratory muscle training and 4 weeks of functional inspiratory muscle training. The training program will be held every day of the week, with 3 of those days conducted under the supervision of a physiotherapist.

    Other: Inspiratory Muscle Training · Other: Functional Inspiratory Muscle Training

  • No intervention
    Controlled group

    Participants in this group will continue with their routine daily lives.

Interventions

  • OtherInspiratory Muscle Training

    Moderate-intensity basic inspiratory muscle training will be provided using a threshold pressure loading device (POWERBreathe) for the first four weeks, starting at 30% of MIP and gradually increasing to 50% depending on the participant's tolerance. The training will be conducted twice daily, 15 minutes in the morning and 15 minutes in the evening, for a total of 30 minutes. With the device, the patient will perform 5-10 deep breathing cycles, then remove the device and perform 3-5 calm breaths to control their breathing. At the end of each day, the physiotherapist will communicate with the patients to assess their progress in the exercise and record it in the exercise log.

  • OtherFunctional Inspiratory Muscle Training

    Following basic IMT, simultaneous exercises (wall plank, wall lateral bridge, wall bridge, shoulder flexion/abduction, elbow flexion, trunk rotation, squat-stand, standing leg raise, walking) will be performed for 4 weeks. Abdominal muscle activation will be taught at the beginning of the training, and functional exercises, paying attention to abdominal stabilization, will continue throughout the training sessions. Moderate intensity IMT will be applied, starting from 30% of the MIP and increasing up to 50% depending on the participant's tolerance. While using the device, the patient will take 5-10 deep breaths and simultaneously perform the functional exercises in sequence, each with 5-10 repetitions/sets (1-3 sets per day). Then, they will remove the device from their mouth and practice breath control by taking 3-5 calm breaths. Exercises that the patient cannot perform will be recorded.

06

What researchers measure

Primary outcomes

  1. Inspiratory Muscle Strength

    Inspiratory muscle strength will be assessed with a spirometer. The highest value for inspiratory pressure will be recorded.

    Time frame: Baseline and after 8-week

  2. Expiratory Muscle Strength

    Expiratory muscle strength will be assessed with a spirometer. The highest value for expiratory pressure will be recorded.

    Time frame: Baseline and after 8-week

Secondary outcomes

  1. Quality of Life Score

    The Pediatric Quality of Life Inventory 3.0 Cardiac Module will be assessed using Turkish versions of the 8-12 and 13-18 year old child and parent forms. A minimum score of 0 and a maximum score of 100 can be obtained on the scale; a higher score indicates a higher quality of life.

    Time frame: Baseline and after 8-week

  2. Exercise Capacity measurement

    Maximal exercise capacity will be assessed using the Incremental Shuttle Walk Test. The number of shuttles completed after the test will be recorded.

    Time frame: Baseline and after 8-week

  3. Measurement of Functional Capacity

    Functional capacity will be assessed using the 1-minute sit-to-stand test, and the number of sit-to-stand repetitions performed in one minute will be recorded.

    Time frame: Baseline and after 8-week

  4. Grip strength measurement

    Grip strength will be measured using a standard, adjustable, and portable hydraulic hand dynamometer.

    Time frame: Baseline and after 8-week

  5. Measurement of Back and Leg Strength

    Back and leg strength will be measured using a Saehan standard platform back-leg-chest dynamometer. The best value recorded from the dynamometer after three trials will be noted in kilograms.

    Time frame: Baseline and after 8-week

  6. Forced vital capacity (FVC)

    Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.

    Time frame: Baseline and after 8-week

  7. Forced expiratory volume in the first second (FEV1)

    Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.

    Time frame: Baseline and after 8-week

  8. FEV1/FVC

    Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.

    Time frame: Baseline and after 8-week

  9. Flow rate 25-75% of forced expiratory volume (FEF 25-75%)

    Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.

    Time frame: Baseline and after 8-week

  10. Peak flow rate (PEF)

    Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.

    Time frame: Baseline and after 8-week

07

Study locations

1 site
08

References and documents

Publications

  • Arnouts EC, Drysdale ND, Gerstner Saucedo J, Gonzalez de Alba C, Malone LJ, Fonseca B, DiMaria MV, Browne LP, Barker AJ. Examination of elevated myocardial extracellular volume and exercise capacity in pediatric Fontan patients at moderate altitude. Pediatr Radiol. 2026 Sep;56(10):2260-2271. doi: 10.1007/s00247-026-06675-2. Epub 2026 Jun 3. PubMed 42233987 ↗
  • Haas SD, van der Hulst AE, Widyanti AP, van Schuppen J, Oosterlaan J, van den Aardweg JG, Ten Harkel ADJ, Kuipers IM, Blom NA. Cardiorespiratory fitness in children with surgically corrected congenital heart disease: Exercise testing profiles and biventricular function. Am Heart J. 2026 Aug 26;303:107590. doi: 10.1016/j.ahj.2026.107590. Online ahead of print. PubMed 42648610 ↗
  • Dorobantu DM, van de Bruaene A, Budts W, Cifra B, Friedberg MK, Fritsch P, Khoury M, Muller J, Opotowsky A, Sanatani S, Williams C, Hansmann G, Pieles GE. Sports and Supervised Exercise Programmes for Children and Young Adults with Pulmonary Hypertension. 2026 Consensus Statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN) and the Association for European Paediatric and Congenital Cardiology (AEPC). J Heart Lung Transplant. 2026 Jul 29:S1053-2498(26)02015-2. doi: 10.1016/j.healun.2026.07.026. Online ahead of print. PubMed 42526776 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2028, 20 months later.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 20 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854171
Lead sponsor
Izmir Democracy University
Responsible party
Gulsah Bargi (Associate Professor Dr, Izmir Democracy University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Gülşah Barğı, Assoc Prof
Contact
gulsahbargi35@gmail.com
+90 232 299 0739
Berfin Kişin Sarıoğlu, MSc, PT
Contact
kisinberfin@gmail.com
+905394671464
Gülşah Barğı, Assoc Prof
study director · Izmir Democracy University
Berfin Kişin Sarıoğlu, MSc PT
principal investigator · Izmir Democracy University
Sema Savcı, Prof
principal investigator · Acibadem University
Mustafa Kır, Prof
principal investigator · Dokuz Eylul University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion